Description and costs of the management of non-alcoholic fatty liver disease (NAFLD) in France (in diabetic and non-diabetic patients) (quid nash)

QUID-NASH is addressing a major bottleneck in the management of Non-Alcoholic SteatoHepatitis (NASH) associated to Type 2 Diabetes (T2D): the access to liver tissue. The project aims at delivering multimodal non-invasive biomarkers to constitute a virtual liver biopsy for NASH diagnostic and staging, to be made widely available for frontline physicians and for clinical trials; and for the assessment of mechanistic pathways, to be made available to NASH scientists, particularly for drug development. To compare the impact of virtual liver biopsy to the current strategy for NASH in diabetic patients, we will combine microcosting data on the resources used to perform the virtual biopsy with data on the current management of NASH. Objectives: - Estimate the overall cost of NAFLD for the social health insurance - Estimate the cost per patient for a diagnosed NAFLD - Model, at the individual and at the collective level, the effect of introducting a virtual biopsy and possibly a treatment.